Roivant Sciences (ROIV) director gets fully vested 670-share award

Rhea-AI Filing Summary

Epperly Melissa B, reported acquisition or exercise transactions in this Form 4 filing.

Roivant Sciences Ltd. director Melissa B. Epperly received a grant of 670 Common Shares as equity compensation. The award was made under the company’s Non-Employee Director Compensation Plan and was fully vested on the grant date. Following this grant, she directly holds 16,474 Common Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Epperly Melissa B,

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	670	$0.00	--

Holdings After Transaction: Common Shares — 16,474 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 670 Common Shares Post-transaction holdings: 16,474 Common Shares Grant price per share: $0.0000 per share

3 metrics

Shares granted 670 Common Shares Equity award to director on grant date

Post-transaction holdings 16,474 Common Shares Director’s direct ownership after grant

Grant price per share $0.0000 per share Indicates non-cash compensation award

Key Terms

Non-Employee Director Compensation Plan, Common Shares, Grant, award, or other acquisition

3 terms

Non-Employee Director Compensation Plan financial

"received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested"

Common Shares financial

"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Epperly Melissa B,

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	04/17/2026		A		670(1)	A	$0(1)	16,474	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

Remarks:

	By: /s/ Jo Chen, as Attorney-in-Fact for Melissa B. Epperly	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ROIV director Melissa Epperly report?

Director Melissa B. Epperly reported receiving a grant of 670 Roivant Sciences Common Shares. The award was issued at no cash cost under the Non-Employee Director Compensation Plan and represents equity-based compensation rather than an open-market purchase or sale.

How many Roivant Sciences (ROIV) shares does the director hold after this grant?

After the reported grant, Melissa B. Epperly directly holds 16,474 Common Shares of Roivant Sciences Ltd. This figure includes the 670-share award received on the transaction date, as disclosed in the filing’s post-transaction ownership information.

Was the ROIV share award to the director immediately vested?

Yes. The 670-share award to Melissa B. Epperly was fully vested as of the grant date. This means the director had full ownership and rights in those Common Shares immediately when they were granted under the Non-Employee Director Compensation Plan.

Did the Roivant Sciences director pay cash for the 670-share grant?

No cash payment was involved for the 670-share grant to Melissa B. Epperly. The Form 4 shows a price per share of $0.0000, indicating the Common Shares were issued as compensation rather than purchased in an open-market or private cash transaction.

What type of transaction is reported in this Roivant Sciences Form 4?

The Form 4 reports a grant or award acquisition of Common Shares to director Melissa B. Epperly. The transaction code is “A,” described as a grant, award, or other acquisition, and reflects non-derivative equity compensation under the Non-Employee Director Compensation Plan.